some times i do not want to add to much in the replies because its a lot more involved than folks think.
and i get moaned at for posting ........🤣 |
Killer whale ? Don't you mean damp squib,..
.
.
'risk dissipates with price'?
What is the idiot talking about ? Jeez |
also this Renal cell doublet is in "First line" treatment
its really important if your spending a lot of money on the trial to get the patients first rather than after a failure from another treatment
"the right setting" |
so you see getting the technical data with Doublet = Massive value added across the platform
we have synergy Modi1 and Pd-1
next stop
Simon Stage 1 ........ 19 patients doublet
if that does not work the trial stops (balanced posting) |
proof of further study requirements we saw in Iscib1
Scancell has also received MHRA correspondence requesting a preclinical mouse safety study with iSCIB1+ prior to resubmission of the amendment to the current trial protocol to include a new parallel cohort with the double CPIs with iSCIB1+.
Management do not see any potential issue with this regulatory request having previously completed identical studies with SCIB1. The iSCIB1+ cohort is now expected to start in Q1 2024. |
Thank you Marcus. That answers the one question that I hadat the back of my mind.
A major could pay, in the meantime, press on with renal a head and neck. |
Marcus, Many thanks for the reply. You seem to be of similar opinion to burble that it is largely down to money. |
defiantly ...
trouble is unless folks read the posts and take it in ... then they are worth diddly squat
Ruck's memory only lasted 24hrs, he had forgotten my reply and ask the same question again |
Good for everyone else to know maybe. Ovarian could be a promising trial with CPIs. |
marcus i had already replied to Ruck yesterday
Ruck is just being Ruck again ... |
our Killer whale is so smart it could lure a turkey for the kill. here is a killer whale baiting a bird so he can eat the bird ... |
Just looking on LSE re Ruck`s question;
Q
"So what happened to the other two targets? Particularly the ovarian patient(s) who had promising results. Have there been official announcements from the company or have they just been quietly dropped?"
A.
Check points are not approved for Ovarian so they would cost Scancell a fortune to try that combination. Big pharma will probably try it when licensed.
CTLA-4 and PD-1 is approved for Renal RCC, PD-1 for head & neck so push ahead with those two initially.
Head & Neck is a cold tumour so these results have been excellent.
Doublet will probably work better in H&N too.
(HNSCC tissues are in an immunosuppressive state, with fewer lymphocytes, natural killer (NK) cells and specific antigens than normal tissues. Thus, this cancer type is called a “cold tumour”. HNSCC can escape immune surveillance through different mechanisms.) |
oh no ... not two types of vaccine in one again ....
must be something to do with the "one immune system" |
here is another snippet from Scancells extensive reservoir of scientific papers
this is on the potency of long term memory ... and how wide the effects of a therapeutic vaccine for one cancer can act as a Prophylactic for another cancer type
Mice surviving the primary melanoma B16 tumor also rejected a subsequent rechallenge with the same tumor (p<0.0001) (figure 4D). Survivors of primary melanoma challenge were also assessed for protection against rechallenge with the LLC/2 lung tumor cell line, known to express vimentin and enolase and constitutively expressing HLA-DP4. Without any further vaccination, the previously Modi-1 immunized and challenged mice showed a significant delay in tumor growth (p=0.0007) when rechallenged with a different tumor when compared with unimmunized mice |
yes that would be a Killer Whale ... extremely smart Mammal .. which is not a Fish Lozan
however i could see you getting confused because it looks like one ...
and yes they can eat prey on the beach without paying with bitcoin |
Local delivery
Preclinical studies indicate that intratumoral administration of CTLA-4 blocking antibody in a low dose is as effective
In advanced NSCLC, a relatively low dose of anti-CTLA-4, 25 mg for quavonlimab and 1 mg/kg for ipilimumab, administered every 6 weeks in ...
The use of low-dose combination checkpoint inhibition appears to be a promising approach for improving clinical benefit without significantly increasing adverse ... |
Many multiples -
For those who first were attracted to SCLP by this 'statement', that FAILED to materialise, most have moved-on.
However, a small 'gang' saw the chance to 'clean-up' by overstating the 'riches to come' ...still 'at it' over 12 YEARS on.
Der leader of this 'group' may appear to think,in ALL matters, HE is the biggest fish in the sea
Whereas, REALITY shows = HE is the biggest fish on the beach |
anyway good to see Burble explain to Ruck what commercial business plans look like
and why companies like Scancell structure them for max financial gain from funds available |
I just remember Lindy saying that the vaccines stimulate T Cells but when they go inside a solid tumour can get switched off. The check points protect them and they can do their job.
Re the Neoadjuvant arm of Modi-1 in H&N then they are hopefully close to proving Modi-1`s method of operation.
That coupled with more good results in H&N and Renal in H2 may be enough to convince the big boys to licence at least Modi-1.
In the meantime maybe Genmab starting phase I with SC129 would be great news. |
 its interesting when you look at Rucks posting history ... how the word "dropped" has yet again cropped up ! This time he is asking the Audience, probably hoping for another £199 buy and he feels he can influence. 🤣
So here is today's attempt at negativity
RuckRover
Posts: 5,585
Price: 9.00
No Opinion
Modi1 TrialToday 08:43
When the MODI1 trial was registered on clinical trials, four targets were listed:
Head and Neck
Renal
Ovarian
TN breast cancer
The 2023 year end statement mentions encouraging results in ovarian cancer. More recently, only head and neck and renal cancers are mentioned.
So what happened to the other two targets? Particularly the ovarian patient(s) who had promising results. Have there been official announcements from the company or have they just been quietly dropped?
and here is yesterday
RuckRover - 05 Feb 2025 - 09:01:27 - 17397 of 17491 Scancell - Pot of Gold or POS? - SCLP
Inan,
A nice upbeat post highlighting the scientific theory.
Reminds me of the initial excitement surrounding the Moditope discovery, the fantastic results seen in laboratory mice and the assertion that tumours just "melt away". This, coupled with the claim Moditope would work standalone saw the share price go from 15p to 60p over a three month period.
That was over 12 years ago. The reality has been a little different. In actual human trials, tumours haven't "melted away" and it has been discovered that Moditope will need help from checkpoint inhibitors. One cancer target has been dropped from the trial. These factors has seen the share drop to a 12 month low just over 9p.
So by all means, keep spouting the theory meanwhile the market will assess the facts.
I have every expectation that the "self harm bully boy Club"
Will come out in support of Group think |
from the man that thinks risk dissipates with price !
your really do post some nonsense !
"news follows price"
yet Bitcoin follows Trump 🤣
Best place for you Turkey is "oven ready"
anyway another day for you Turkey, collecting benefit and watching wealth move around
2tyke SMBTS (sad man behind the screen) |
'News desperately needed'
.
Hmmm....at this stage Nigel i'd be careful what you wish for.
News follows price...it doesn't lead. |
If you look at the non- recurrence rate after surgery without Pd-1 its in the 80% bracket, once we have OS data and PFs data from the current trials of Modi1 , it will give an indication on how good Modi1 works on recurrence of distant mets ie. "fresh lesions" which effectively is what neoadjuvant treatment is doing, because in our current trial, Ctl-4 is used only at very early stage ie first few months. Basically Modi1 will be on its own anyway in year 3 or 4, if you then get recurrence, hit it hard with systemic double checkpoint which is at a far higher dose than early adjuvant setting otherwise you are treating the 80% that don't need it with Pd-1 adding toxicity. I strongly believe Modi1 needs the cancer present to activate fully and could be given on day one of diagnose activating while the patient waits surgery.
will check dosage from the trial tomorrow of Pd-1 adjuvant compared to systemic treatment
I don't think Scancell can drop the dosage of ctl-4 its critical to get those T regs turned off once modi1 has control they will not dominate anyway as they are Plastic they may differentiate back to helper t cell rather than suppressor which is why its given short term |
I already said its a $1b min development project |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
